EUVIMEDEUVIMED entdecken
Crossref

Harnessing a Light-Activated Ruthenium(II) Complex Self-Delivery Nanoplatform for Tumor–Organelle Cascade-Targeted Immunotherapy via Type II Immunogenic Cell Death

Jun Wang, Tao Kuang, Bin Hu, Jun Yin, Zongtao Zhou, Guixiu Qin, Suisui He, Cui-Yun Yu iD, Hua Wei iD

ACS Applied Materials & Interfaces · 04.11.2026 · 18 (43) · 59088-59102

DOI: 10.1021/acsami.6c18179 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 20.10.2026. Verfasst von Jun Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, Universi…. Hauptthemen laut MEDLINE: Ruthenium, Immunogenic Cell Death, Immunotherapy, Nanoparticles. Die Arbeit nennt 69 Literaturangaben. Gefördert von: Education Department of Hunan Province, Key Project of Research and Development Plan of Hunan Province, Hunan Science and Technology Innovation Leading Talent Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunogenic cell death (ICD) converts immunosuppressive “cold” tumors into immunogenic “hot” ones, yet ICD inducers with precise tumor–organelle cascade targeting and spatiotemporal controllability remain largely unexplored. Herein, we report a self-delivery nanoplatform (ER-Ru NPs) constructed via the self-assembly of well-defined tumor–endoplasmic reticulum (ER) cascade-targeting ruthenium(II) complexes. The intrinsic amphiphilicity enables self-assembly of the ruthenium(II) complexes into stabilized nanoparticles with efficient tumor accumulation properties via biotin-mediated active targeting, without any exogenous carriers. Following cellular internalization, the released ruthenium(II) complex monomer specifically accumulates in the ER to generate a cleaved Ru–H2O anticancer agent and in situ reactive oxygen species (ROS) upon red-light irradiation. The robust ROS burst triggers severe ER stress via activation of the PERK/eIF2α pathway, leading to the release of damage-associated molecular patterns and the type II ICD induction. Notably, this cascade-targeted ICD activation strategy enhances not only tumor specificity but also the immunogenicity of dying tumor cells, achieving effective primary tumor ablation in the 4T1 models and simultaneously suppressing distant tumors through dendritic cell maturation, cytotoxic T-cell infiltration, and memory T-cell generation. This study offers a paradigm for photoactivatable, self-delivery ICD inducers with cascade targeting, holding substantial promise for clinical translation in precision cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RutheniumImmunogenic Cell DeathImmunotherapyNanoparticlesAntineoplastic AgentsCoordination ComplexesAnimalsMiceReactive Oxygen SpeciesFemaleCell Line, TumorHumansRed LightMice, Inbred BALB C

Stichwörter der Autor:innen

cascade targetingimmunogenic cell deathphotoactivated chemotherapyruthenium complexself-delivery

Substanzen

RutheniumReactive Oxygen SpeciesAntineoplastic AgentsCoordination Complexes

Autor:innen und Institutionen

  • Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang421001, China.
  • Affiliated Hospital of Hunan Academy of Chinese Medicine, Hunan Academy of Chinese Medicine, Changsha410013, China.

ORCID-Profile: Cui-Yun Yu, Hua Wei

Förderung

  • Education Department of Hunan Province
  • Key Project of Research and Development Plan of Hunan Province
  • Hunan Science and Technology Innovation Leading Talent Project
  • National Natural Science Foundation of China (NSFC)
  • Foundation of Hunan Provincial Natural Science Foundation of China

Zitieren

APA

Wang, J., Kuang, T., Hu, B., Yin, J., Zhou, Z., Qin, G., He, S., Yu, C. Y., & Wei, H. (2026). Harnessing a Light-Activated Ruthenium(II) Complex Self-Delivery Nanoplatform for Tumor–Organelle Cascade-Targeted Immunotherapy via Type II Immunogenic Cell Death. ACS Applied Materials & Interfaces, 18(43), 59088-59102. https://doi.org/10.1021/acsami.6c18179

Vancouver

Wang J, Kuang T, Hu B, Yin J, Zhou Z, Qin G, et al. Harnessing a Light-Activated Ruthenium(II) Complex Self-Delivery Nanoplatform for Tumor–Organelle Cascade-Targeted Immunotherapy via Type II Immunogenic Cell Death. ACS Applied Materials & Interfaces. 2026;18(43):59088-59102. doi:10.1021/acsami.6c18179

BibTeX
@article{Wang2026,
  author = {Wang, Jun and Kuang, Tao and Hu, Bin and Yin, Jun and Zhou, Zongtao and Qin, Guixiu and He, Suisui and Yu, Cui-Yun and Wei, Hua},
  title = {Harnessing a Light-Activated Ruthenium(II) Complex Self-Delivery Nanoplatform for Tumor–Organelle Cascade-Targeted Immunotherapy via Type II Immunogenic Cell Death},
  journal = {ACS Applied Materials & Interfaces},
  year = {2026},
  volume = {18},
  number = {43},
  pages = {59088--59102},
  doi = {10.1021/acsami.6c18179}
}
Kostenlos starten →